XX中药单体对肿瘤多药耐药的逆转作用及其机制研究

批准号:
39970853
项目类别:
面上项目
资助金额:
13.0 万元
负责人:
刘耕陶
依托单位:
学科分类:
H3505.抗肿瘤药物药理
结题年份:
2002
批准年份:
1999
项目状态:
已结题
项目参与者:
黄敏、余凌红、魏怀玲
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
肿瘤多药耐药(MDR)是肿瘤化疗失败的主要原因之一,研究MDR耐药的机制及寻找能逆转MDR的新药是国际上研究热点之一。我们新筛选到XX中药的一种单体LC及其粗提取物LCC在体舛远嘀种琢鱿赴闙DR有很强的逆转作用。LC在浓度为25uM时对VCR的逆转倍数可达300倍,而LC是一个与国内外现有的MDR逆转剂结构完全不同的天然成分。本项目拟围绕MDR的相关靶标,对LC及LCC逆转MDR作用的分子机制及其体内逆转肿瘤耐药的活性进行深入研究,以探讨LC及LCC本身作为新药开发的可能性。故本项目具有高度的原始创新性和我国自己的知识
英文摘要
The present study discovers the mutidrug resistance (MDR) reversing activity of Chinese traditional medicine XX extract in vitro and in vivo, in which LC is the primary active component exhibiting MDR reversal action. XX extract and LC give significant reversal of resistance to vincristine, adriamycin and paclitaxel dose-dependently in a panel of required and innate MDR cell lines. The potency of XX extract and LC are much greater than that of verapamil, a classic MDR reversal agent. The ability of XX extract to reverse MDR in vivo is demonstrated using nude mice bearing KBv200 xenografts. XX extract itself also shows anticancer activity at higher doses without toxic effects. In the mechanism study, LC is found to increase the intracellular accumulation of anticancer drugs in MDR tumor cells through inhibiting the overexpression of P-glycorprotein at both mRNA and protein levels. Moreover, the reversal activity of LC may also be related to the increased susceptibility of MDR tumor cells to apoptosis induced by anticancer cells. The structure of LC are different from any of the classes of the known MDR reversal agents, and the source of XX is very rich in China. So XX extract and its active component LC may be developed as a MDR reversal agent, combined with anticancer drugs that are developed MDR by tumors easily to increase their anticancer activities, or developed as an anticancer agent. Now we are applying for the patent of XX and LC. Furthermore, we have found the MDR reversal activity of a drug which has been used in clinic in China for years. All of its reversal pharmacological tests are finished and its patent is under the authorization of Chinese Patent Bureau now. We also investigated the mechanism of required 5-FU resistance in Bel7402/5-FU cells. The results have been published in World Journal of gastroenterology.
专著列表
科研奖励列表
会议论文列表
专利列表
肿瘤多药耐药机制及其逆转剂先导化合物的应用基础研究
- 批准号:30630069
- 项目类别:重点项目
- 资助金额:150.0万元
- 批准年份:2006
- 负责人:刘耕陶
- 依托单位:
几种五味子素对大鼠脑细胞凋亡及有关基因表达的影响
- 批准号:39870865
- 项目类别:面上项目
- 资助金额:11.0万元
- 批准年份:1998
- 负责人:刘耕陶
- 依托单位:
抗肝炎新药SY-801阻抑肝细胞甲胎蛋白分泌及基因表达
- 批准号:39470829
- 项目类别:面上项目
- 资助金额:7.5万元
- 批准年份:1994
- 负责人:刘耕陶
- 依托单位:
五味子酚和丹酚酸A对中性粒细胞杀菌调节机理的影响
- 批准号:39170232
- 项目类别:面上项目
- 资助金额:3.0万元
- 批准年份:1991
- 负责人:刘耕陶
- 依托单位:
国内基金
海外基金
